发表论文：

（1）      Liu, X., Song, Y., Cheng, P., Liang, B., & Xing, D. (2024). Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes. Cancer Treatment Reviews, 102826.

（2）      Liu, X., Ma, L., Li, J., Sun, L., Yang, Y., Liu, T., ... & Zhang, M. (2024). Trop2-targeted therapies in solid tumors: advances and future directions. Theranostics, 14(9), 3674.

（3）      Deng, J., Geng, Z., Luan, L., Jiang, D., Lu, J., Zhang, H., ... Liu, X.*, & Xing, D.* (2024). Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth. Pharmaceutics, 16(10), 1255.

（4）      Huang, B., Liu, X., & Xing, D. (2024). Recent advances in water-soluble polythiophenes for biomedical applications. European Polymer Journal, 113096.

（5）      Yan, S., Liu, Q., Liu, Z., Liu, R., Xing, K., Zhang, M., ... Liu, X.*, & Xing, D.* (2024). Gel-confined fabrication of fully bio-based filtration membrane for green capture and rapid detection of airborne microbes. Journal of Colloid and Interface Science, 670, 417-427. 

（6）      Shao, Y., Xu, J., Chen, W., Hao, M., Liu, X., Zhang, R., ... & Dong, Y. (2024). miR-135b: an emerging player in cardio-cerebrovascular diseases. Journal of Pharmaceutical Analysis, 100997.

（7）      Shao, Y., Liu, T., Wen, X., Zhang, R., Liu, X.*, & Xing, D.* (2023). The regulatory effect of growth differentiation factor 11 on different cells. Frontiers in Immunology, 14, 1323670.

（8）      Yan, S., Liu, Q., Xing, K., Liu, Z., Guo, H., Jiang, W., ... & Liu, X.*, Xing, D.* (2024). Versatile filter membrane for effective sampling and real-time quantitative detection of airborne pathogens. Journal of Hazardous Materials, 474, 134740.

（9）      Chen, W., Wu, Y., Wang, J., Yu, W., Shen, X., Zhao, K., ... & Xing, D. (2024). Clinical advances in TNC delivery vectors and their conjugate agents. Pharmacology & Therapeutics, 253, 108577.

（10）   Liu, X., Li, J., Deng, J., Zhao, J., Zhao, G., Zhang, T., ... & Wang, J. (2023). Targeting Trop2 in solid tumors: a look into structures and novel epitopes. Frontiers in Immunology, 14, 1332489.

（11）   Liu, X., Deng, J., Zhang, R., Xing, J., Wu, Y., Chen, W., ... & Zhang, M. (2023). The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy. Frontiers in Immunology, 14, 1335252.

（12）   Yuan, Y., Liang, B., Liu, X. L., Liu, W. J., Huang, B. H., Yang, S. B., ... & Xing, D. M. (2022). Targeting NAD+: is it a common strategy to delay heart aging?. Cell death discovery, 8(1), 230.

（13）   Zhang, M., Xing, J., Zhong, Y., Zhang, T., Liu, X.*, & Xing, D.* (2023). Advanced function, design and application of skin substitutes for skin regeneration. Materials Today Bio, 100918.

（14）   Zhao, D.*, Liu, L.*, Liu, X.*, Zhang, J., Yin, Y., Luan, L., ... & Huang, H. (2022). A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA. 1 through a unique binding mode. Journal of Nanobiotechnology, 20(1), 411.

（15）   Chen, W., Xing, J., Liu, X., Wang, S., & Xing, D. (2021). The role and transformative potential of IL-19 in atherosclerosis. Cytokine & Growth Factor Reviews, 62, 70-82.

（16）   Liang, B., Yuan, Y., Peng, X. J., Liu, X. L., Hu, X. K., & Xing, D. M. (2022). Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics. Frontiers in cellular and infection microbiology, 12, 1042070.

（17）   Xing, J., Zhang, M., Liu, X., Wang, C., Xu, N., & Xing, D. (2023). Multi-material electrospinning: from methods to biomedical applications. Materials Today Bio, 100710.

（18）   Liu, X.*, Deng, J.*, Yuan, Y., Chen, W., Sun, W., Wang, Y., ... & Xing, D. (2022). Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer. Pharmacology & Therapeutics, 239, 108296.

（19）   Liu, X.*, Chen, J.*, Wang, Z.*, Wang, D., He, M., Qian, C., Song, S., Chi, X., Kong, Z., Zheng, Q., et al. (2019). Neutralization sites of human papillomavirus-6 relate to virus attachment and entry phase in viral infection. Emerg Microbes Infect 8, 1721-1733.

（20）   Wang, D.*, Liu, X.*, Wei, M.*, Qian, C., Song, S., Chen, J., ... & Chi, X. (2020). Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. Nature Communications, 11(1), 1-15.

（21）   Qian, C*., Liu, X.*, Xu, Q., Wang, Z., Chen, J., Li, T., ... & Xia, N. (2020). Recent Progress on the Versatility of Virus-Like Particles. Vaccines, 8(1).

（22）   Chen, W., Xing, J., Liu, X., Wang, S., & Xing, D. (2021). The role and transformative potential of IL-19 in atherosclerosis. Cytokine & Growth Factor Reviews.

（23）   He, M., Chi, X., Zha, Z., Li, Y., Chen, J., Huang, Y., Huang, Shi., Yu, Miao., Wang, Zhi., Song, Shuo., Liu, X., ... & Xia, N. (2021). Structural basis for the shared neutralization mechanism of three classes of human papillomavirus type 58 antibodies with disparate modes of binding. Journal of Virology, 95(7), e01587-20.

（24）   Zheng, Q.*, Jiang, J.*, He, M.*, Zheng, Z., Yu, H., Li, T., Xue, W., Tang, Z., Ying, D., Li, Z., Song, S., Liu, X.et al. (2019). Viral neutralization by antibody-imposed physical disruption. Proc Natl Acad Sci U S A.

（25）   Li, Z.*, Song, S.*, He, M.*, Wang, D., Shi, J., Liu, X., Li, Y., Chi, X., Wei, S., Yang, Y., et al. (2018). Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity. Nature Communications9, 5360.

（26）   Li, Z.*, Wang, D.*, Gu, Y., Song, S., He, M., Shi, J., Liu, X., Wei, S., Li, J., Yu, H., et al. (2017). Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus. mBio 8, 17.

（27）   Wang, D.*, Fan, F.*, Li, Z., Liu, X., Song, S., Wei, S., He, M., Lin, Y., Li, Z., Wei, M., et al. (2017). Stop codon mutagenesis for homogenous expression of human papillomavirus L1 protein in Escherichia coli. Protein Expr Purif 133, 110-120.

（28）   Xia, L.*, Xian, Y.*, Wang, D., Chen, Y., Huang, X., Bi, X., Yu, H., Fu, Z., Liu, X., Li, S., et al. (2016). A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5. Scientific Reports 6.

主持或参与项目：

（1）      国家自然科学基金青年项目：32300788，新型Trop2双表位抗体的抗肿瘤机制和结构基础；2024/01-2026/12；30万元；主持。

（2）      山东省自然科学基金青年项目：ZR2022QH201，三阴性乳腺癌新型多功能治疗性抗体开发和抗肿瘤机制研究；2023/01-2025/12；15万元；主持。

（3）      山东省自然科学基金面上项目：ZR2024MC119，靶向阻断Trop2二聚化和多聚化的新型双特异性抗体的抗肿瘤机制和结构基础；2025/01-2027/12；10万元；主持。

（4）      国家自然科学基金重大项目：81991491，结构指导的免疫原设计及广谱保护机制研究；2020/01-2024/12；370.0万元；在研、参与。

（5）      国家科技重大专项新药创制项目：2018ZX09738-008，重组人乳头瘤病毒16/18型双价疫苗的III期临床研究和产业化；2018/01-2020/12；791.1万元；结题、参与。

（6）      国家自然科学基金面上项目：81971932，基于锁定人乳头瘤病毒L1和L2衣壳蛋白间相互作用的L2结构解析和功能研究; 2020/01-2023/12；55.0万元；在研、参与。